Global Elrantamab Market Strategic Research Report

Scope of the Report

The global Elrantamab market size is predicted to grow from US$ 297 million in 2025 to US$ 1,143 million in 2032; it is expected to grow at a CAGR of 13.4% from 2026 to 2032.

Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, indicated for the treatment of relapsed or refractory multiple myeloma. The drug can simultaneously bind to BCMA antigen on the surface of myeloma cells and CD3 antigen on the surface of T cells. By bridging tumor cells and T cells, it activates T cells to specifically kill tumor cells. As a T-cell redirecting immunotherapeutic agent, it is characterized by high targeting specificity and significant anti-tumor activity.In 2025, global Elranatamab production reached approximately 51000——52000 vials.

Elranatamab is a humanized bispecific monoclonal antibody targeting BCMA/CD3, mainly used for the treatment of relapsed or refractory multiple myeloma, and is one of the core agents in the field of T-cell redirecting immunotherapy. With a clear mechanism of action, it activates anti-tumor immunity by bridging myeloma cells and T cells. Clinical studies have confirmed that it exhibits deep and durable efficacy in heavily pretreated patients, and is recommended by authoritative guidelines such as the US NCCN and Chinese CSCO, with a clear market positioning.

In terms of the competitive landscape, the drug, together with similar BCMA/CD3 bispecific antibodies including Johnson & Johnson’s Teclistamab, constitutes an important therapeutic option for multiple myeloma, while facing competition from CAR-T therapies. Its differentiation is reflected in its administration route and tolerability profile. Elranatamab has been approved in major markets worldwide including the United States, the European Union and China, with commercial layout covering multiple regions. Continuous clinical development, including combination therapies and exploration of first-line indications, provides long-term momentum for market expansion.

As an important layout of Pfizer in the field of tumor immunology, the drug relies on the company’s marketing channels and R&D resources, and is expected to occupy an important position in the bispecific antibody market for multiple myeloma. Meanwhile, it will promote the popularization and application of BCMA-targeted therapeutic regimens and become a key force in innovating the treatment landscape of this field.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Elrantamab market?

What factors are driving Elrantamab market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Elrantamab market opportunities vary by end market size?

How does Elrantamab break out by Type, by Application?

This report presents a comprehensive overview of the global Elrantamab market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 44 mg / 1.1 mL
• 76 mg / 1.9 mL

Segment by Dosage Form

• Subcutaneous Injection Solution
• Lyophilized Powder for Injection

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Antibody Type

• Monoclonal Antibody
• Polyclonal Antibody
• Bispecific Antibody

Segment by Application

• Monotherapy for Relapsed or Refractory Multiple Myeloma
• Combination Therapy with Immunomodulators and Proteasome Inhibitors
• Exploration in First-Line or Second-Line Treatment of Multiple Myeloma
• Otherts

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Elrantamab market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Monotherapy for Relapsed or Refractory Multiple Myeloma, Combination Therapy with Immunomodulators and Proteasome Inhibitors, Exploration in First-Line or Second-Line Treatment of Multiple Myeloma evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact